Key Takeaways:
Zealand Pharma said its experimental obesity drug, co-developed with Roche, showed encouraging tolerability in a mid-stage trial, strengthening the case for a gentler alternative to the blockbuster GLP-1 treatments dominating the $92 billion market.
"The tolerability profile we observed supports the potential for this therapy to address a key unmet need in obesity care," a Zealand Pharma spokesperson said, declining to provide specific adverse event rates before full data disclosure at a medical conference.
The Phase 2 study evaluated the amylin-based therapy, which Zealand and Roche are developing under a partnership valued at up to $5.3 billion announced in March 2025. Amylin analogs target a different metabolic pathway than the GLP-1 receptor agonists sold by Novo Nordisk and Eli Lilly, potentially offering fewer gastrointestinal side effects that have led to high discontinuation rates with existing treatments.
The positive tolerability readout comes as the obesity drug market undergoes a seismic shift. Eli Lilly overtook Novo Nordisk as the GLP-1 market leader in early 2026, with Mounjaro and Zepbound sales surging 125% and 80% respectively in the first quarter, according to IndexBox data. IQVIA forecasts obesity medicine sales will reach $92 billion this year and as much as $200 billion by 2027, drawing a wave of competitors seeking to challenge the duopoly.
Roche has positioned itself as a potential top-three player in obesity, with its dual GLP-1/GIP agonist CT-388 showing a 22.5% placebo-adjusted weight reduction in Phase 2 data released in January. The Zealand-partnered amylin program gives Roche a second, differentiated asset that could be used as a monotherapy or in combination with CT-388.
For Zealand, the data validates its strategy of pursuing a tolerability-first approach rather than competing solely on weight-loss efficacy. The Danish biotech's other obesity asset, survodutide — licensed to Boehringer Ingelheim — showed a 16.6% weight reduction in Phase 3, positioning it closer to Novo's Wegovy than Lilly's Zepbound on efficacy but with potentially better quality weight loss driven by fat reduction.
The tolerability data strengthens Zealand's hand as it prepares for the next phase of development. Investors will watch for full efficacy and safety results, expected at a major medical conference later this year, which will determine whether the amylin approach can carve out a meaningful share of the rapidly expanding obesity market.
This article is for informational purposes only and does not constitute investment advice.
